Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women.
The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p < 0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.
Proudler
A J
AJ
Wynn Department of Metabolic Medicine, National Heart and Lung Institute, London, UK.
Ahmed
A I
AI
Crook
D
D
Fogelman
I
I
Rymer
J M
JM
Stevenson
J C
JC
D003327:Coronary Disease / Q000517:prevention & control; D004958:Estradiol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000627:therapeutic use; D007703:Peptidyl-Dipeptidase A / Q000097:blood*; D017698:Postmenopause / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors
D004966:Estrogens, Conjugated (USP); D004958:Estradiol; D007703:Peptidyl-Dipeptidase A; D009640:Norethindrone